Treatment of Autoimmune Diseases by Modulating Bregs (No. T4-1441)


Chronic lymphocytic leukemia (CLL), a malignant disease characterized by the accumulation of B lymphocytes in the blood, lymphoid organs, and bone marrow, is the second most common type of leukemia in adults, accounting for about 7,000 new cases of leukemia each year. Presently, there is no cure for CLL, and the overall goal of leukemia treatment is to bring about a remission. Therefore, identifying new proteins that may serve as a target for inducing cell death in the malignant cells is highly desirable. The present technology identifies a new regulator protein that is essential for the survival of CLL cells.


• Diagnosis of CLL


• Very specific to malignant B cells • Diagnosis, and therefore treatment, can be made at early stages of the disease

Technology's Essence

B cells taken from CLL patients have a high level of the protein CD84. Stimulation of CD84 upregulates the survival of B-CLL. However, inhibition of CD84 activity with a blocking antibody downregulates the expression of another protein which controls B-CLL survival, thus inducing cell death. Therefore, the present invention reveals CD84 as a regulator of B-CLL survival

Patent Status: 
USA Granted: 10,611,839 USA Granted: 9,109,029 USA Granted: 10,329,347 USA Granted: 10,828,318 USA Granted: 8,686,121 USA Granted: 10,066,014
Full Professor Idit Shachar

Idit Shachar

Faculty of Biology
All projects (2)
Contact for more information

Dr. Yael Klionsky

Director of Business Development, Life Science

+972-8-9344293 Linkedin